Drug major GlaxoSmithKline (GSK) has unethically tested a breast cancer drug on poor patients in India for approval for new drugs in the Europe Union, said a study. According to an investigation by Mumbai-based Centre for Studies in Ethics and Rights, the firm tested lapatinib on patients flouting Indian Council of Medical Research's (ICMR) ethical guidelines.This trial required seriously ill patients who had not received treatment for their condition.
GlaxoSmithKline on Wednesday applied for approval to market its breast cancer drug Tykerb in U.S. and Europe as a first-line treatment for women with advanced, hormone-sensitive breast cancer, the AP/Google.com reports. Tykerb, know... Read Post
An examination of the potential interaction between pharmaceutical companies and the U.S. Food and Drug Administration (FDA) to discuss future studies finds that one-quarter of recent new drug approvals occurred without any meeting,... Read Post